Beyond Air, Inc. (NASDAQ:XAIR – Get Free Report) CEO Robert Scott Goodman acquired 34,722 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was bought at an average cost of $5.76 per share, for a total transaction of $199,998.72. Following the completion of the transaction, the chief executive officer directly owned 34,822 shares of the company’s stock, valued at $200,574.72. This trade represents a 34,722.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Beyond Air Stock Down 2.6%
Shares of XAIR traded down $0.14 during midday trading on Friday, reaching $5.28. 27,954 shares of the company were exchanged, compared to its average volume of 168,749. Beyond Air, Inc. has a 1-year low of $5.02 and a 1-year high of $95.60. The stock has a 50-day moving average price of $7.75 and a 200-day moving average price of $14.27. The company has a current ratio of 3.80, a quick ratio of 3.59 and a debt-to-equity ratio of 3.48. The company has a market cap of $3.81 million, a price-to-earnings ratio of -0.06 and a beta of 0.22.
Beyond Air (NASDAQ:XAIR – Get Free Report) last posted its earnings results on Friday, June 26th. The company reported ($15.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($11.33) by ($4.07). Beyond Air had a negative net margin of 432.99% and a negative return on equity of 350.00%. The company had revenue of $1.91 million during the quarter, compared to analyst estimates of $2.30 million.
Hedge Funds Weigh In On Beyond Air
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Beyond Air in a research report on Tuesday, July 21st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $200.00.
View Our Latest Research Report on Beyond Air
About Beyond Air
Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.
The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.
Further Reading
- Five stocks we like better than Beyond Air
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.
